---
title: "Biofrontera Inc. (BFRI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BFRI.US.md"
symbol: "BFRI.US"
name: "Biofrontera Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T02:04:07.003Z"
locales:
  - [en](https://longbridge.com/en/quote/BFRI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BFRI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BFRI.US.md)
---

# Biofrontera Inc. (BFRI.US)

## Company Overview

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.biofrontera-us.com](https://www.biofrontera-us.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:13.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 100 / 190 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 13.70% |  |
| Net Profit YoY | 3.82% |  |
| P/B Ratio | 1.57 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 9540004.83 |  |
| Revenue | 43201000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -339.04% | E |
| Profit Margin | -25.66% | E |
| Gross Margin | 79.02% | A |
| Revenue YoY | 13.70% | B |
| Net Profit YoY | 3.82% | C |
| Total Assets YoY | 49.43% | A |
| Net Assets YoY | 1194.24% | A |
| Cash Flow Margin | 84.02% | C |
| OCF YoY | 13.70% | B |
| Turnover | 2.09 | A |
| Gearing Ratio | 75.51% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Biofrontera Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "13.70%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "3.82%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.57",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "9540004.83",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "43201000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-339.04%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-25.66%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "79.02%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "13.70%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "3.82%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "49.43%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "1194.24%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "84.02%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "13.70%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "2.09",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "75.51%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.87 | 99/190 | - | - | - |
| PB | 1.59 | 77/190 | 17.14 | 12.11 | 1.17 |
| PS (TTM) | 0.22 | 10/190 | 0.28 | 0.25 | 0.22 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.81 |
| Highest Target | 9.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/BFRI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/BFRI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/BFRI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/BFRI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**